Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEAMERICAN:BPMXNYSE:CYBNOTCMKTS:NGENFNYSEAMERICAN:PFNX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBPMXBiopharmx$0.00$0.25▼$6.30$111.86MN/A2.15 million shs336,508 shsCYBNCybin$7.98+8.1%$7.59$4.81▼$13.88$183.62M0.68279,729 shs442,098 shsNGENFNervGen Pharma$2.45+1.4%$2.83$1.46▼$5.10$151.58MN/A144,152 shs74,801 shsPFNXPfenex$12.75$12.75$5.26▼$14.00$437.29MN/A503,865 shsN/A2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBPMXBiopharmx0.00%0.00%0.00%0.00%0.00%CYBNCybin-18.00%-10.65%-8.89%+23.83%+1,900.00%NGENFNervGen Pharma-2.81%-10.70%-6.20%+12.04%+18.63%PFNXPfenex0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBPMXBiopharmxN/AN/AN/AN/AN/AN/AN/AN/ACYBNCybin2.7075 of 5 stars3.60.00.00.02.40.81.3NGENFNervGen PharmaN/AN/AN/AN/AN/AN/AN/AN/APFNXPfenexN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBPMXBiopharmx 0.00N/AN/AN/ACYBNCybin 3.25Buy$86.00978.37% UpsideNGENFNervGen Pharma 3.00BuyN/AN/APFNXPfenex 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest NGENF, PFNX, CYBN, and BPMX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025NGENFNervGen PharmaRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform5/13/2025CYBNCybinCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBPMXBiopharmxN/AN/AN/AN/AN/AN/ACYBNCybinN/AN/AN/AN/A$10.83 per shareN/ANGENFNervGen Pharma$150K1,010.56N/AN/AN/A∞PFNXPfenexN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBPMXBiopharmxN/AN/A0.00N/AN/AN/AN/AN/AN/ACYBNCybin-$57.88M-$4.38N/AN/AN/AN/A-37.58%-36.59%N/ANGENFNervGen Pharma-$4.07MN/AN/A∞N/AN/A-73.14%-56.59%8/20/2025 (Estimated)PFNXPfenexN/AN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBPMXBiopharmxN/AN/AN/AN/AN/ACYBNCybinN/AN/AN/AN/AN/ANGENFNervGen PharmaN/AN/AN/AN/AN/APFNXPfenexN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBPMXBiopharmxN/AN/AN/ACYBNCybinN/A24.2424.24NGENFNervGen Pharma0.0411.2111.21PFNXPfenexN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBPMXBiopharmxN/ACYBNCybin17.94%NGENFNervGen PharmaN/APFNXPfenexN/AInsider OwnershipCompanyInsider OwnershipBPMXBiopharmxN/ACYBNCybin15.00%NGENFNervGen PharmaN/APFNXPfenexN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBPMXBiopharmx1718.28 millionN/ANot OptionableCYBNCybin5023.02 million17.96 millionNot OptionableNGENFNervGen Pharma761.77 millionN/ANot OptionablePFNXPfenex7134.30 millionN/ANot OptionableNGENF, PFNX, CYBN, and BPMX HeadlinesRecent News About These CompaniesUCB posts more supportive data from Humira rival bimekizumabNovember 6, 2024 | pharmaphorum.comPNKY Medical Holdings Ltd Class A 300109January 31, 2024 | morningstar.comMLast available seats at PFS West Coast Conference next weekMay 19, 2023 | pharmaphorum.comPLigand Pharmaceuticals and Playa Hotels Resorts Exceed Q1 ... - Best StocksMay 4, 2023 | news.google.comN150+ Active Companies working to develop 160+ Pipeline ... - Digital JournalApril 12, 2023 | news.google.comNHere's Why You Should Add Ligand (LGND) Stock to Your Portfolio - NasdaqApril 6, 2023 | news.google.comNLENZ Therapeutics Closes $83.5M Series B - San Diego Business JournalMarch 29, 2023 | news.google.comNRanibizumab Biosimilars Report 2023: Therapies and Ranibizumab ... - Digital JournalMarch 17, 2023 | news.google.comNGlobal Inflammatory Bowel Disease (IBD) Therapeutics Market to ... - GlobeNewswireMarch 15, 2023 | news.google.comNSan Diego's Lenz Therapeutics snags $83.5M for once-a-day eye ... - The San Diego Union-TribuneMarch 15, 2023 | news.google.comNOsteoporosis Treatment research scope: In-depth Growth Analysis ... - Digital JournalMarch 13, 2023 | news.google.comNCurrent and Future Analysis of Osteoporosis Treatment Market With New Business Strategies and Forecast by 2030 - openPRMarch 1, 2023 | news.google.comNLigand Reports Fourth Quarter and Full Year 2022 Financial Results - The Bakersfield CalifornianFebruary 23, 2023 | news.google.comNLigand Reports Fourth Quarter and Full Year 2022 Financial Results - Business WireFebruary 22, 2023 | news.google.comNBiosimilar Growth Hormones Global Market Report 2023 - Yahoo FinanceFebruary 8, 2023 | news.google.comNBiosimilar Therapeutic Peptides Global Market Report 2023 - Yahoo FinanceFebruary 8, 2023 | news.google.comNOsteoporosis Treatment Market Set to Witness Explosive Growth By ... - Digital JournalFebruary 7, 2023 | news.google.comNInjectable Drug Delivery Market Dynamic Demand, Growth ... - PharmiWeb.comJanuary 27, 2023 | news.google.comNOsteoporosis Treatment Market Research Scope: In-Depth Growth ... - Digital JournalJanuary 27, 2023 | news.google.comNInjectable Drug Delivery Market 2023 Segmentation and Regional Analysis by 2032 - openPRJanuary 6, 2023 | news.google.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNGENF, PFNX, CYBN, and BPMX Company DescriptionsBiopharmx NYSEAMERICAN:BPMXBioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women's health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort, as well as alleviates the symptoms of fibrocystic breast condition (FBC). Its clinical-stage product candidates include BPX01, a topical antibiotic gel that has completed Phase II clinical trials for the treatment of inflammatory lesions of acne; BPX04, a topical antibiotic, which is in pre-Phase II feasibility study for the treatment of inflammatory lesions of rosacea; BPX02, a development stage product candidate for aesthetic dermatology applications; and BPX03, a molecular iodine tablet, which has completed pre-Phase III clinical trial for the treatment of periodic breast pain associated with FBC and cyclic mastalgia. The company serves pharmaceutical companies; physician's practices, including obstetricians and gynecologists, dermatologists, and general practitioners; and retail customers through retail sales channels and/or pharmacy outlets. It has collaboration and license agreement with Iogen LLC to develop molecular iodine formulations; and collaboration and supply agreement with NuTech Medical, Inc. to develop products in the field of dermatology. The company is headquartered in Menlo Park, California.Cybin NYSE:CYBN$7.98 +0.60 (+8.06%) Closing price 03:58 PM EasternExtended Trading$7.96 -0.01 (-0.19%) As of 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.NervGen Pharma OTCMKTS:NGENF$2.45 +0.03 (+1.40%) As of 12:56 PM EasternNervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. It has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.Pfenex NYSEAMERICAN:PFNX$12.75 0.00 (0.00%) As of 10/1/2020Pfenex Inc., a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study. The company also develops PF582, a biosimilar candidate to Lucentis; PF529, a biosimilar to Neulasta; and hematology/oncology products, including PF743, a recombinant crisantaspase, as well as PF745, a recombinant crisantaspase with half-life extension technology. In addition, it has license and supply agreements for CRM197, a non-toxic mutant of diphtheria toxin. Pfenex Inc. is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Nike's Stock Just Got an Upgrade: Is a Real Comeback Brewing? Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
